G Bellone, C Rollino, S Borsa, I Ferrero, G Martina, A Carbone, K Mareschi, F Quarello, G Piccoli, G Emanuelli, L Matera
{"title":"Association between elevated prolactin levels and circulating erythroid precursors in dialyzed patients.","authors":"G Bellone, C Rollino, S Borsa, I Ferrero, G Martina, A Carbone, K Mareschi, F Quarello, G Piccoli, G Emanuelli, L Matera","doi":"10.1046/j.1525-1373.2000.22352.x","DOIUrl":null,"url":null,"abstract":"<p><p>The prolactin (PRL) receptor (R), a member of the cytokine hemopoietin receptor superfamily, has been shown to activate early differentiation steps along the erythroid pathway. In particular PRL, a product of bone marrow stroma, induces functional erythropoietin (EPO)-R on CD34+ hemopoietic progenitors. In this study, expression of EPO-R mRNA and responsiveness to EPO were assessed on enriched hemopoietic progenitor cells (HPC) from seven hyperprolactinemic and three normoprolactinemic patients and two normal subjects. Expression of EPO-R mRNA by semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was found in HPC of four out of seven hyperprolactinemic patients but not in normoprolactinemic patients or normal donors. Development of EPO-dependent Colony Forming Unit-Erythroid (CFU-E) colonies in semi-solid medium was observed only in hyperprolactinemic patients (six out of seven). A much higher number of CFU-E colonies was observed in the four patients with a positive EPO-R message. We conclude from these data that abnormally high levels of PRL may increase the number of EPO-responsive hemopoietic precursors in vivo as they do in vitro. Since hyperprolactinemia associates in these patients with depressed EPO production, it may be regarded as a compensatory mechanism for the reduced availability of the hemopoietic factor.</p>","PeriodicalId":20675,"journal":{"name":"Proceedings of the Society for Experimental Biology and Medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2000-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Proceedings of the Society for Experimental Biology and Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1046/j.1525-1373.2000.22352.x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 10
Abstract
The prolactin (PRL) receptor (R), a member of the cytokine hemopoietin receptor superfamily, has been shown to activate early differentiation steps along the erythroid pathway. In particular PRL, a product of bone marrow stroma, induces functional erythropoietin (EPO)-R on CD34+ hemopoietic progenitors. In this study, expression of EPO-R mRNA and responsiveness to EPO were assessed on enriched hemopoietic progenitor cells (HPC) from seven hyperprolactinemic and three normoprolactinemic patients and two normal subjects. Expression of EPO-R mRNA by semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was found in HPC of four out of seven hyperprolactinemic patients but not in normoprolactinemic patients or normal donors. Development of EPO-dependent Colony Forming Unit-Erythroid (CFU-E) colonies in semi-solid medium was observed only in hyperprolactinemic patients (six out of seven). A much higher number of CFU-E colonies was observed in the four patients with a positive EPO-R message. We conclude from these data that abnormally high levels of PRL may increase the number of EPO-responsive hemopoietic precursors in vivo as they do in vitro. Since hyperprolactinemia associates in these patients with depressed EPO production, it may be regarded as a compensatory mechanism for the reduced availability of the hemopoietic factor.
催乳素(PRL)受体(R)是细胞因子造血素受体超家族的一员,已被证明可以激活红细胞途径的早期分化步骤。特别是骨髓基质产物PRL,可诱导CD34+造血祖细胞上的功能性促红细胞生成素(EPO)-R。本研究对7例高泌乳素血症患者和3例正常泌乳素血症患者及2例正常人的造血祖细胞(HPC)进行了EPO- r mRNA的表达和对EPO的反应性评估。通过半定量逆转录聚合酶链反应(RT-PCR)在7例高泌乳素血症患者中的4例HPC中发现了EPO-R mRNA的表达,而在正常泌乳素血症患者或正常供体中未发现。在半固体培养基中,仅在高泌乳素血症患者(7例中有6例)中观察到epo依赖性集落形成单位-红系(CFU-E)集落的发展。在EPO-R信息阳性的4例患者中观察到更多的CFU-E菌落。我们从这些数据中得出结论,体内异常高水平的PRL可能会增加epo反应性造血前体的数量,就像它们在体外一样。由于高催乳素血症在这些患者中与EPO产生降低有关,因此它可能被视为造血因子可用性降低的代偿机制。